Where is Ethyreal Bio located?

Ethyreal Bio is headquartered in Cambridge, United States.

Who is the current CEO of Ethyreal Bio?

Niranjan Kameswaran and Niranjan Kameswaran s of Ethyreal Bio.

How many employees does Ethyreal Bio have?

As of Apr 30, 2026, the latest employee count at Ethyreal Bio is 12.

Is Ethyreal Bio a funded company?

Ethyreal Bio is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Ethyreal Bio rank among its competitors?

Ethyreal Bio ranks 2614th amongst 3215 active competitors, of which 1109 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Ethyreal Bio?

Ethyreal Bio's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Ethyreal Bio - 2026 Company Profile, Team & Competitors

Ethyreal Bio is an unfunded company based in Cambridge (United States). It operates as a Developer of therapeutics for immuno-oncological conditions. Ethyreal Bio has not raised any funding yet. The company has 3215 active competitors, including 1109 funded and 761 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of therapeutics for immuno-oncological conditions. The company is developing prominent immunology drugs for various cancer conditions.

Key Metrics

Location

Cambridge, United States

Stage

Unfunded

Ranked

2614^th among 3215 active competitors

Employee Count

12 as on Apr 30, 2026

Similar Companies

BeiGene & 539 more

View Ethyreal Bio's full profile

Ethyreal Bio has not raised any funding rounds yet.

Ethyreal Bio's employee count trend

Ethyreal Bio has 12 employees as of Apr 26. Here is Ethyreal Bio's employee count trend over the years:

Uncover Ethyreal Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ethyreal Bio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Ethyreal Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	73/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	73/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 18 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	71/100
2614th	Ethyreal Bio Cambridge (United States), Unfunded	Developer of therapeutics for immuno-oncological conditions	-	-	27/100